Guggenheim lowers ArriVent BioPharma stock price target to $28
Guggenheim cut its price target on ArriVent BioPharma (AVBP) to $28 from $30, keeping a Buy rating. The stock is down 53% in six months, trading at $13.01. The firm adjusted estimates after Q3 2026 results, including a Phase 3 miss for FURVENT. ArriVent has $393.2M in cash, expected to last until mid-2028. Analysts have mixed views on its prospects.
